Study of Value of Dexamethasone Used in Ovulation Induction

Sponsor

Reproductive & Genetic Hospital of CITIC-Xiangya (Other)

Overall Status

Withdrawn

CT.gov ID

NCT03421041

Collaborator

(none)

Enrollment

Location

Arms

35.9

Actual Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study intends to solve the following problems: whether use dexamethasone can obviously decrease transplant cancelling probability in fresh embryo transplant cycle or not, reduce time and frequency going to hospital repeatedly for patients need frozen embryo transplant or not, and reduce the economic burden for patients or not; By comparing pregnancy rate of single transplant, hope to make clear in IVF-ET treatment for patients progesterone increases to a certain level whether it is a good choice to transfer fresh embryo after dexamethasone treatment, or frozen embryo transplant is better.

Condition or Disease	Intervention/Treatment	Phase
Infertility, Female	Drug: Dexamethasone Oral Tablet	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A RCT Study of Value of Dexamethasone Used in Ovulation Induction

Actual Study Start Date :

Apr 1, 2018

Actual Primary Completion Date :

Sep 30, 2020

Actual Study Completion Date :

Mar 30, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Dexamethasone group	Drug: Dexamethasone Oral Tablet Dexamethasone Oral Tablet，0.75mg/tablet
No Intervention: control group

Arm

Intervention/Treatment

Experimental: Dexamethasone group

Drug: Dexamethasone Oral Tablet

Dexamethasone Oral Tablet，0.75mg/tablet

No Intervention: control group

Outcome Measures

Primary Outcome Measures

cumulative pregnancy rate per oocyte retrieval cycle [Until 28 day after embryo transferred]
cumulative pregnancy rate per oocyte retrieval cycle

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 35 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

female, 18 years old≤age≤35 years old, 18≤BMI≤25, standard patient, menstrual regularity

Exclusion Criteria:

Hyperprolactinemia, Thyroid dysfunction, uterine malformation ( inadequacy mediastinal uterus ≥1.0cm, Unicornate uterus, double uterus, T Angle of uterus, etc.), uterus adhesion, untreated hydrosalpinx , hysteromyoma（ hysteromyoma≥1.0 cm, and/or endometrial hysteromyoma≤1 cm), endometriosis, diabetes, hypertension, adrenal cortex hyperplasia, Cushing's syndrome, a pituitary amenorrhea

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Reproductive & Genetic Hospital of CITIC-XIANGYA	Changsha	Hunan	China	410000

Sponsors and Collaborators

Reproductive & Genetic Hospital of CITIC-Xiangya

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Reproductive & Genetic Hospital of CITIC-Xiangya

ClinicalTrials.gov Identifier:

NCT03421041

Other Study ID Numbers:

LCYJ-201801

First Posted:

Feb 5, 2018

Last Update Posted:

Jan 11, 2022

Last Verified:

Jan 1, 2021

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Infertility

Infertility, Female

Dexamethasone

Study Results

No Results Posted as of Jan 11, 2022